跳转至内容
Merck
CN

Y0000382

法莫替丁

European Pharmacopoeia (EP) Reference Standard

别名:

法莫替丁, N′-(氨基磺酰基)-3-([2-(二氨基亚甲基氨基)-4-噻唑基]甲硫基)丙脒

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C8H15N7O2S3
化学文摘社编号:
分子量:
337.45
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

法莫替丁, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)

SMILES string

N\C(N)=N\c1nc(CSCCC(=N)NS(N)(=O)=O)cs1

InChI key

XUFQPHANEAPEMJ-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

famotidine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... HRH2(3274)

正在寻找类似产品? 访问 产品对比指南

Biochem/physiol Actions

H2组胺受体拮抗剂;抗溃疡剂。

Application

Famotidine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

存储类别

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

I C Wesdorp
Hepato-gastroenterology, 39 Suppl 1, 24-26 (1992-02-01)
Famotidine, a potent and long-acting H2-receptor antagonist, has been evaluated in patients with gastroesophageal reflux disease (GERD). From intraesophageal pH monitoring and clinical studies, b.i.d. dosing of this selective compound is necessary for achieving adequate results. The results of large
K Yoshimoto et al.
Clinical pharmacology and therapeutics, 55(6), 693-700 (1994-06-01)
Central nervous system toxicity of H2-receptor antagonists has rarely been confirmed by the respective elevated cerebrospinal fluid drug concentrations. We observed two hemodialyzed neurosurgical patients in whom mental deterioration and convulsions developed after intravenous famotidine therapy (10 and 40 mg/day).
R R Berardi et al.
Clinical pharmacy, 7(4), 271-284 (1988-04-01)
The pharmacodynamic, therapeutic, and toxicologic properties of famotidine are evaluated and compared with those of cimetidine and ranitidine. Famotidine, an H2-receptor antagonist with a thiazole nucleus, is approximately 7.5 times more potent than ranitidine and 20 times more potent than
H D Langtry et al.
Drugs, 38(4), 551-590 (1989-10-01)
Famotidine is a highly selective histamine H2-receptor antagonist. In healthy volunteers and patients with acid hypersecretory disease it is approximately 20 to 50 times more potent at inhibiting gastric acid secretion than cimetidine and 8 times more potent than ranitidine
C W Howden et al.
Clinical therapeutics, 18(1), 36-54 (1996-01-01)
Famotidine is a specific, long-acting histamine2-receptor antagonist. It is indicated for the treatment of duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Since its introduction for the treatment of acid-related disorders in 1985, an estimated 18.8 million patients

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持